Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: A Multicenter, Randomized Phase II-III Trial

NCT04208347 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04208347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04208347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: A Multicenter, Randomized Phase II-III Trial
Lead sponsor
Ruijin Hospital
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 18, 2019
Completion date
December 31, 2027
Enrollment
580 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

gastric and gastroesophageal junction (gej) adenocarcinoma